Aspire BioPharma is trading up 6.97% at $8.90 on September 28, 2026, with no company-specific catalyst identified. - Latest identified company news predates this session. - Broader markets are lower after President Trump rejected Iran’s peace proposal, pushing oil prices higher and reviving inflation and interest-rate concerns. - Reuters reported the S&P 500 down 0.46% and Nasdaq down 0.65% at 9:51 a.m. ET; the stock’s gain is against the market direction, and the selloff does not explain it.